Company Overview
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
Recent News
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
Stock Overview
Symbol
GTBP
Exchange
Nasdaq
Market Cap
20.4m
Last Price
$0.5641
52-Week Range
$0.4692 - $3.29
03/21/2023 04:00 PM EDT